Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

Carsten Flohra Department of Paediatric Dermatology, St John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation Trust and King’s College London, UKView further author information

Michael J. Corkb Department of Infection, Immunity and Cardiovascular Disease, Sheffield Dermatology Research, University of Sheffield and Sheffield Children’s Hospital, Sheffield, UKView further author information

Michael R. Ardern-Jonesc Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK;d Department of Dermatology, Southampton University Hospitals NHS Foundation Trust, Southampton, UKView further author information

Lawrence F. Eichenfielde Departments of Dermatology and Pediatrics, UC San Diego and Rady Children’s Hospital–San Diego, San Diego, CA, USAView further author information

Sébastien Barbarotf Department of Dermatology, CHU Nantes-Hôtel Dieu, Nantes, FranceView further author information

Claire Feeneyg Pfizer Ltd., Tadworth, Surrey, UKView further author information

Ricardo Rojoh Pfizer Inc., Groton, CT, USAView further author information

Irina Lazariciui Pfizer Inc., New York, NY, USAView further author information

John Nesnasg Pfizer Ltd., Tadworth, Surrey, UKCorrespondence[email protected]
View further author information

show all